Exercise vs Weight Loss Drugs

Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
Half of Americans Support Weight-Loss Drugs Like Ozempic for Obesity, Poll
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching hundreds of dollars per prescription. The poll found that about half of Americans support Medicare and Medicaid covering weight-loss drugs for those with obesity, while around 20 percent oppose it and 25 percent are neutral.
The dark side of weight loss drugs no one warns about
New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these popular medications.
About Half of Americans Approve of Using Weight-Loss Drugs to Treat Obesity, AP-NORC Poll Finds
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and oth
Most Ditch GLP-1 Drugs for Weight Loss Within a Year
Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly higher for patients without versus with type 2 diabetes (64.8% vs 46.5%), reported Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,
The best exercises to do while taking weight loss drugs
Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for people struggling to lose weight. These drugs reduce appetite and sometimes slow digestion which
About half of Americans approve of using weight-loss drugs: Poll
When it comes to ages 12 to 18 who are dealing with obesity, Americans are divided: About one-third say the use of weight-loss drugs in this context is a “very” or “somewhat” good thing, a similar share say it’s a bad thing and about 3 in 10 say it isn’t good or bad.
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Hollywood star feels he’s ‘cheating’ after losing 40 pounds with weight loss drug
Hollywood actor Josh Gad feared his identity would shift after he lost 40 pounds being on a "miracle" weight loss drug.
Josh Gad opens up for 1st time about taking weight loss drug: 'It is life-changing'
During his appearance on the " Armchair Expert " podcast on Monday, the "Frozen" actor opened up about taking weight loss ...
RFK Jr, Dr Oz and weight-loss drugs: A high-price health clash may be looming
Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...
The high cost of weight loss: How patients are fighting for access to breakthrough medications
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Carolyn Hax: Meals with weight-loss-obsessed mom have become unbearable
As Mom loses weight with semaglutide, this letter writer struggles through her incessant food commentary at mealtimes.
Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...